U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07082439) titled 'Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma' on July 08.
Brief Summary: This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Colorectal Adenocarcinoma Metastatic in the Liver
Intervention:
DRUG: Pembrolizumab
Pembrolizumab 200 mg intravenous administration on day 1 of each 3-week cycle until disease progression, unacceptable toxicity or participant withdrawal. Participants who complet...